Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Amplyx, Bayer, Biomarin, Cannabics, Dermtech, Essa, Grifols, Homology, Lilly, Mallinckrodt, Neuraly, Okyo, Pfizer, Point, Silence, Soligenix, Triplet, Twist, VBI, Vifor, Vivlion.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Advanced Biological Laboratories, Fractyl Laboratories, Johnson & Johnson Vision.
Astrazeneca plc’s saga of its COVID-19 vaccine continued this week with the European Commission (EC) deciding to begin legal action against the Cambridge, U.K.-based company, claiming it has failed to deliver doses in line with its contract.
The volume of phase I-III clinical trial data so far in 2021 is a full 26% more than it was by this point last year, yet the proportion of news focused on the COVID-19 pandemic continues at much the same rate.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ampio, Cyclo, Eledon, Enzyvant, Hillhurst, Instil, Krystal, RDIF, Reata, Revive, Rockwell Medical, Sol-Gel Technologies.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aim, Aldeyra, Alkermes, Ampio, Aravive, Brickell, Discgenics, Fosun, Gila, Logicbio, Lumos, Noxopharm, Obseva, Protagonist, Reithera, Revance, Sifi, Verona.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Brainsway, Lucira Health, Neurolutions, Phoenix Cardiac, Speedx.
RSS
